VivoSeq
Other

Double Blind

7

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Double Blind is an early-stage landscape with 7 programs across 6 companies. The most active players are BeiGene, Teva, Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

BeiGene logo

BeiGene

1 program

PreclinicalTeva logo

Teva

1 program

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

PreclinicalA

Avyxa

1 program

PreclinicalM

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

PreclinicalG

Gynecologic Oncology Group

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical7

SCTB41

Sinocelltech Ltd.

Tislelizumab

BeiGene

Paclitaxel

Teva

Nab-Paclitaxel

Bristol-Myers Squibb

Carboplatin

Avyxa

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

86%

Small molecule

6 of 7 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody114%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Multicenter Phase II/III Study Evaluating the Efficacy and Safety of SCTB41 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Driver-Negative Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Recruiting·SSinocelltech Ltd.·Preclinical·NCT07662395·410 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)